Showing results (401-410 of 513) with videos related to
Sort By:
Pageof 52
The Journal of Rheumatology|April 16, 2022
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE StudyTien Nguyen, Melvin Churchill, Robert Levin, et al.The New England Journal of Medicine|October 19, 2017
Tofacitinib or Adalimumab versus Placebo for Psoriatic ArthritisPhilip Mease, Stephen Hall, Oliver FitzGerald, et al.JID Innovations : Skin Science From Molecules to Population Health|August 16, 2024
Prevalence and Impact of Unacceptable Symptom State among Patients with Psoriatic Arthritis: Results from the National Psoriasis Foundation's 2019 Annual SurveyMelissa P Zundell, Alexis R Ogdie-Beatty, Lourdes Perez-Chada, et al.Biorxiv : the Preprint Server for Biology|November 24, 2025
Single Cell Analysis of pBMCs of Psoriasis patients reveals distinct CD4+ T cell phenotypes associated with response to IL-23 blockadeKathryne E Marks, Anina Sun, Ifeoluwakiisi Adejoorin, et al.Rheumatology and Therapy|August 19, 2023
Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis RegistryPhilip J Mease, Alexis Ogdie, John Tesser, et al.The Journal of Investigative Dermatology|October 3, 2024
A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring SystemMaria C Schneeweiss, Robert J Glynn, Richard Wyss, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|February 7, 2020
The National Psoriasis Foundation psoriasis treatment targets in real-world patients: prevalence and association with patient-reported outcomes in the Corrona Psoriasis RegistryJ F Merola, L M Perez Chada, M Siegel, et al.RMD Open|September 28, 2022
Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritisLaura C Coates, Josef S Smolen, Philip J Mease, et al.Rheumatology and Therapy|September 8, 2022
Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation AnalysisKurt de Vlam, Philip J Mease, Andrew G Bushmakin, et al.RMD Open|March 10, 2026
Bimekizumab longer-term safety profile in adult patients with axial spondyloarthritis or psoriatic arthritis: an updated analysis of six phase IIb/III clinical studiesPhilip J Mease, Joseph F Merola, Marina Magrey, et al.Pageof 52